Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines

Inclusion Criteria:

• The subject is aged 2 months (+14 days).

• Male or female.

• Infants who are in good health at the time of entry into the trial as determined bymedical history, physical examination (including vital signs) and clinical judgmentof the investigator.

• The subject's LAR signs and dates a written, informed consent form (ICF) and anyrequired privacy authorization prior to the initiation of any trial procedures,after the nature of the trial has been explained according to local regulatoryrequirements.

• Infants whose LARs can and are willing to comply with trial procedures and areavailable for the duration of follow-up.

Exclusion Criteria:

• Clinically significant abnormality in growth by height, weight, or headcircumference (according to local guidelines).

• Gastrointestinal abnormalities or any chronic gastrointestinal disease, includingany uncorrected congenital malformation of the gastrointestinal tract according tomedical history and/or physical examination.

• Known hypersensitivity or allergy to any of the investigational vaccine components (including excipients).

• Severe reaction to routine childhood vaccine(s) administered at Visit 1.

• Any clinically significant active infection (as assessed by the investigator) ortemperature

≥38.0°C (>100.4°F), within 3 days of intended trial vaccination.

• Any serious chronic or progressive disease according to the judgment of theinvestigator (e.g., cardiac, renal or hepatic disease).

• Individuals with history of, e.g., convulsions/febrile convulsions, or any illness,that, in the opinion of the investigator, might interfere with the results of thetrial or pose additional risk to the subjects due to participation in the trial.

• Known or suspected impairment/alteration of immune function.

• Subjects with a known bleeding diathesis, or any condition that may be associatedwith a prolonged bleeding time.

• Subjects who received or are scheduled to receive any licensed or authorizedvaccines not planned in this trial within 14 days (for inactivated vaccines) orwithin 28 days (for live vaccines) before or after any dose of trial vaccine. Note:Flu and/or COVID vaccine can be administered per local guidelines at any time duringthe trial.

• Subjects participating in any clinical trial with another investigational product 30days prior to first trial visit or due to participate in another clinical trial atany time during the conduct of this trial.

• Subjects known to be positive for or in evaluation for possible humanimmunodeficiency virus infection.

• Subject's LAR or subject's first-degree relatives involved in the trial conduct.